Clinical Trial Update: Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes [Phase 2]

View source ↗

Summary

This report presents Phase 2 safety and efficacy results for CC-486 in patients with Myelodysplastic Syndromes. The study is completed and results were posted o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• CC-486 (azacitidine)

Snippet

Sponsor: Celgene | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2020-07-08